Abstract
Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Volume: 13 Issue: 1
Author(s): Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Massimo Iacoviello and Vincenzo Triggiani
Affiliation:
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Abstract: Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Export Options
About this article
Cite this article as:
Giagulli Vito Angelo, Guastamacchia Edoardo, Pergola Giovanni De, Iacoviello Massimo and Triggiani Vincenzo, Testosterone Deficiency in Male: A Risk Factor for Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010011
DOI https://dx.doi.org/10.2174/1871530311313010011 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Integrating Behavioral Health into a Transplantation Service-One Institution's Approach
Current Psychiatry Reviews The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design HIF Inhibitors: New Hope for Cancer Therapy
Letters in Drug Design & Discovery Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets The Effects of Erythropoietin on the Respiratory Function: Measurements of Respiratory Mechanics in the Rat
Current Respiratory Medicine Reviews Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Association Between Intra-Hospital Uncontrolled Glycemia and Health Outcomes in Patients with Diabetes: A Systematic Review of Observational Studies
Current Diabetes Reviews The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets